Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Earnings
see more| Q2 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2021-08-03 | ||||||
| REV | |||||||
| Q1 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2021-05-21 | ||||||
| REV | |||||||
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BMEA | Biomea Fusion | -0.82% |
Biomea Fusion Company Questions & Answers
Q
How do I buy Biomea Fusion (BMEA) stock?
A
You can purchase shares of Biomea Fusion (NASDAQ: BMEA) through any online brokerage.
Q
Who are Biomea Fusion's (BMEA) main competitors?
A
There are no as such competitors for Biomea Fusion.
Q
What is the target price for Biomea Fusion?
A
There is no analysis for Biomea Fusion
Q
How much is Biomea Fusion (BMEA) stock ?
A
The stock price for Biomea Fusion (NASDAQ: BMEA) is $16.94 last updated Fri May 07 2021 20:00:02 GMT+0000 (Coordinated Universal Time).
Q
When is the next Biomea Fusion (BMEA) dividend?
A
There are no upcoming dividends for Biomea Fusion.
Q
When is Biomea Fusion (NASDAQ:BMEA) reporting earnings?
A
Biomea Fusion’s Q2 earnings are confirmed from now on August 3, 2021.
Q
When is the upcoming split for BMEA?
A
There is no upcoming split for Biomea Fusion.